Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
OptiNose, Inc. (OPTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Second Quarter 2023 Financial Results and Operational Updates Optinose Reports Second Quarter 2023 Financial Results and Operational Updates Optinose Reports Second Quarter 2023 Financial Results and Operational Updates",
"Q2 2023 30.1 30.9 Q2"
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports First Quarter 2023 Financial Results and Operational Updates Optinose Reports First Quarter 2023 Financial Results and Operational Updates Optinose Reports First Quarter 2023 Financial Results and Operational Updates",
"Q1 2023 29.5 30.4 Q1"
03/07/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights",
"2 0 2 3 EXHIBIT 99.2"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
11/16/2021 8-K Investor presentation
Docs: "Q3 2021 69.0 86.3 Q3"
08/11/2021 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights",
"Q2 2021 62.5 82.9 Q2"
03/03/2021 8-K Quarterly results
11/05/2020 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights",
"62.5 60 54.3 56.1 43.0"
08/04/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/12/2019 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net revenues for 2019 to be in the range of $29 - $34 million Conference call and webcast to be held today at 4:30 p.m. Eastern Time",
"OptiNose, Inc. Corporate Presentation"
06/04/2019 8-K Investor presentation
Docs: "Optinose, Inc. Corporate Presentation"
05/09/2019 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights Company reports first quarter 2019 total revenues of $4.5 million. XHANCE first quarter net product revenues grew to $4.0 million XHANCE prescriptions increased 59% from fourth quarter 2018 to first quarter 2019 Conference call and webcast to be held today at 8:00 a.m. Eastern Time",
"OptiNose, Inc. Corporate Presentation"
03/06/2019 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018 Conference call and webcast to be held today at 8:00 a.m. Eastern Time",
"OptiNose, Inc. Corporate Presentation"
12/12/2018 8-K Investor presentation
Docs: "Optinose, Inc. Corporate Presentation"
11/13/2018 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to be held today at 8:00 a.m. Eastern Time",
"OptiNose, Inc. Corporate Presentation"
10/01/2018 8-K Quarterly results
08/14/2018 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch Conference call and webcast to be held today at 8:00 a.m. Eastern Time",
"OptiNose, Inc. Corporate Presentation"
05/14/2018 8-K Quarterly results
04/09/2018 8-K Investor presentation
Docs: "Corporate Presentation"
03/13/2018 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights Optinose expects early April availability of XHANCE in retail pharmacies XHANCE Xperience program launched in early March",
"Optinose, Inc. Corporate Presentation"
11/15/2017 8-K Investor presentation
Docs: "Corporate Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy